ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of 978,995. The enterprise value is 8.26 million.
| Market Cap | 978,995 |
| Enterprise Value | 8.26M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 4.62 million shares outstanding. The number of shares has increased by 94.71% in one year.
| Current Share Class | 4.62M |
| Shares Outstanding | 4.62M |
| Shares Change (YoY) | +94.71% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.22% |
| Owned by Institutions (%) | 6.56% |
| Float | 4.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| PB Ratio | 0.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.20 |
| EV / Sales | 1.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.77 |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of 1.12.
| Current Ratio | 0.14 |
| Quick Ratio | 0.07 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.72 |
| Interest Coverage | -7.28 |
Financial Efficiency
Return on equity (ROE) is -220.34% and return on invested capital (ROIC) is -44.99%.
| Return on Equity (ROE) | -220.34% |
| Return on Assets (ROA) | -23.50% |
| Return on Invested Capital (ROIC) | -44.99% |
| Return on Capital Employed (ROCE) | -284.31% |
| Revenue Per Employee | 52,656 |
| Profits Per Employee | -434,417 |
| Employee Count | 96 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, ProPhase Labs has paid 15.18 million in taxes.
| Income Tax | 15.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.09% in the last 52 weeks. The beta is -0.54, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.54 |
| 52-Week Price Change | -97.09% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 3.31 |
| Relative Strength Index (RSI) | 16.51 |
| Average Volume (20 Days) | 2,957,716 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of 5.06 million and -41.70 million in losses. Loss per share was -11.64.
| Revenue | 5.06M |
| Gross Profit | 987,000 |
| Operating Income | -29.61M |
| Pretax Income | -34.38M |
| Net Income | -41.70M |
| EBITDA | -24.22M |
| EBIT | -29.61M |
| Loss Per Share | -11.64 |
Balance Sheet
The company has 405,000 in cash and 7.68 million in debt, with a net cash position of -7.28 million or -1.58 per share.
| Cash & Cash Equivalents | 405,000 |
| Total Debt | 7.68M |
| Net Cash | -7.28M |
| Net Cash Per Share | -1.58 |
| Equity (Book Value) | 6.86M |
| Book Value Per Share | 1.65 |
| Working Capital | -47.51M |
Cash Flow
In the last 12 months, operating cash flow was -10.63 million and capital expenditures -40,000, giving a free cash flow of -10.67 million.
| Operating Cash Flow | -10.63M |
| Capital Expenditures | -40,000 |
| Free Cash Flow | -10.67M |
| FCF Per Share | -2.31 |
Margins
| Gross Margin | 19.53% |
| Operating Margin | -585.78% |
| Pretax Margin | -680.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -94.71% |
| Shareholder Yield | -94.71% |
| Earnings Yield | -4,259.88% |
| FCF Yield | -1,090.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 22, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
ProPhase Labs has an Altman Z-Score of -3.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.5 |
| Piotroski F-Score | 1 |